Answers are grounded in this paper and cite their sources.
Demonstrates improved tissue healing in congenital heart disease treatment, suggesting a new coating strategy.
Minimally invasive occluder implantation effectively treats congenital heart disease by sealing cardiac defects. However, it still faces issues of inadequate endothelialization and tissue healing capabilities in clinical practice. In this study, we propose an extracellular matrix (ECM)-biomimetic microenvironment-regulating coating, where a polyethylene glycol linker (alkyne-PEG-silane) with antifouling effects is used to graft tailored recombinant humanized collagen type I (rhCol I) possessing high cell-adhesive activity via an efficient click reaction. In vitro blood and cell experiments reveal that this coating improves hemocompatibility, promotes endothelial cell growth, and enhances cardiomyocyte function. Subcutaneous and intravascular implantations confirm the coating's ability to alleviate inflammation by polarizing inflammatory cells into an anti-inflammatory phenotype, accelerate endothelialization, and facilitate tissue repair. This work highlights the potential effectiveness of the coating in optimizing the performance of cardiac occluders, which could be a promising strategy for improving the clinical efficacy of occluders.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: